Chang Xiaofeng, Liu Tieshi, Zhang Fan, Ji Changwei, Zhao Xiaozhi, Wang Wei, Guo Hongqian
Department of Urology, the Affiliated Nanjing Drum Tower Hospital, Medical School of Nanjing University , Nanjing, Jiangsu, China .
J Endourol. 2015 May;29(5):518-25. doi: 10.1089/end.2014.0864. Epub 2015 Feb 18.
To compare outcomes in patients treated with radiofrequency ablation (RFA) and partial nephrectomy (PN) for clinical T1a renal-cell carcinoma (RCC) in a propensity-score matched cohort.
We conducted a retrospective review of the records of all patients who underwent RFA or nephrectomy between February 2005 and December 2009 in our institution. The Kaplan-Meier method was used to generate the survival curves that were compared with the log-rank test. Univariable and multivariable regression analyses were performed to determine predictors of survival.
A total of 90 patients were included in the final study after being matched by propensity scores (RFA 45; PN 45). The 5-year overall survival (95% confidence interval [CI]) was 90.2% (78.6-98.8) vs 93.2% (85.8-98.9); 5-year cancer-specific survival (95% CI) was 95.6% (89.5-98.1) vs 97.7% (93.4-99.3); 5-year disease-free survival (95% CI) was 86.7% (89.5-96.7) and 88.5% (79.1-97.9); 5-year recurrence-free survival (95% CI) was 95.4% (89.3-98.1) vs 97.7% (93.3-99.2); and 5-year metastasis-free survival (95% CI) was 95.5% (89.4-98.0) vs 95.5% (89.4-98.0). Age was the only factor that could predict the disease-free survival (P=0.044). The percentage decrease in the glomerular filtration rate was significantly lower in the RFA group at the time of last follow-up (P=0.001).
In the propensity-score matched cohort of patients with clinical T1a RCC, we observed that RFA was an effective treatment option that provided comparable 5-year oncologic outcomes and better preservation of renal function than PN.
在倾向评分匹配队列中比较接受射频消融(RFA)和部分肾切除术(PN)治疗的临床T1a期肾细胞癌(RCC)患者的治疗结果。
我们对2005年2月至2009年12月期间在本机构接受RFA或肾切除术的所有患者的记录进行了回顾性分析。采用Kaplan-Meier方法生成生存曲线,并通过对数秩检验进行比较。进行单变量和多变量回归分析以确定生存预测因素。
通过倾向评分匹配后,最终研究纳入了90例患者(RFA组45例;PN组45例)。5年总生存率(95%置信区间[CI])分别为90.2%(78.6-98.8)和93.2%(85.8-98.9);5年癌症特异性生存率(95%CI)分别为95.6%(89.5-98.1)和97.7%(93.4-99.3);5年无病生存率(95%CI)分别为86.7%(89.5-96.7)和88.5%(79.1-97.9);5年无复发生存率(95%CI)分别为95.4%(89.3-98.1)和97.7%(93.3-99.2);5年无转移生存率(95%CI)分别为95.5%(89.4-98.0)和95.5%(89.4-98.0)。年龄是唯一可预测无病生存的因素(P=0.044)。末次随访时,RFA组肾小球滤过率的下降百分比显著更低(P=0.001)。
在倾向评分匹配的临床T1a期RCC患者队列中,我们观察到RFA是一种有效的治疗选择,其5年肿瘤学结果与PN相当,且肾功能保留优于PN。